LNTH recently purchased cancer drugs license which are in the Phase 1 with FDA, that look promising. The company raised some cash through senior convertible notes. Quarterly revenue grew 134% YoY to $239.3mm, driven by strengths across the portfolio. Management raised Q4 and FY22 guidance to the upside from the top-bottom lines. Last ER looks like: Lantheus...
Uptrend on weekly and daily. HH HL HH HL. Expecting a bounce off the zone where it's currently at, as it closed as a hammer on the daily. A lot more open interest and volume on the call side. The only thing I don't like is the spread on the options isn't too tight. Trim as it hits the next zone and my main pt is the top of the last higher high.
Lantheus Holdings ( NASDAQ:LNTH ) has been on a major run recently after an earnings beat. Insiders started selling shares ($3.3 million) in late February/early March 2022 after it popped from the $28s to a current high of $54.10. It is highly overextended and has hit it's historical resistance based on the highs from 2015 and 2017 (blue resistance line on the...
– No interconnectable formations within main formation – No leg since mid 2016 (extremely bearish), must return to lower trend line – Significant volume drop (below average), sharp corrections expected – Unbroken PSAR series from 2016 to 2018 will now be mirrored in a down trend – 8 out of 9 indicators point to much lower stock value, 1 'neutral Very straight...